Fig. 1: STING agonists induce the secretion of a unique cytokine portfolio. | Cell Death Discovery

Fig. 1: STING agonists induce the secretion of a unique cytokine portfolio.

From: STING agonists trigger monocyte death via apoptosis, pyroptosis, caspase-8 activation and mitochondrial dysfunction

Fig. 1

Human PBMCs (n = 5–7 donors) were treated for 16 h with TLR agonists: TLR7 agonist GS-9620, TLR3 agonist poly I:C (HMW), TLR9 agonist CpG-A (ODN2216), TLR7/8 agonist Resiquimod, TLR2/7 agonist Adilipoline, and STING agonists: diaminobenzimidazole-based agonist (diABZI), 3′,3′c-di(2′F,2′d-AMP) (3′3′cdiFAA) and 2′,3′-cGAMP (2′3′cGA). Untreated cells (UT) were used as control samples. The concentration of secreted cytokines in the medium was multiplexed using ProcartaPlex Immunoassays (type I interferons, IFNs: IFNα, IFNβ, IFNω; type II IFN: IFNγ; type III IFN: IFNλ1 (IL29); proinflammatory cytokines: tumor necrosis factor alpha (TNFα), interleukin-1β (IL1β), IL18, IL6). Data were analyzed using the Friedman test with uncorrected Dunn’s test for multiple comparisons. Individual donors are represented by different symbols. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page